OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models
AUTHORS
Chen, et al
Programs
OPN-TEAD
Download PDF
OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC
AUTHORS
Matusow, et al
Programs
OPN-6602
Download PDF
OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription in mCRPC
AUTHORS
Matusow, et al
Programs
OPN-6602
Download PDF
Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cancer
AUTHORS
Swisher, et al
Programs
OPN-2853
Download PDF
Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma
AUTHORS
Gordon, et al
Programs
OPN-2853
Download PDF
Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
AUTHORS
Mims, et al
Programs
OPN-2853
Download PDF
Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
AUTHORS
Pemmaraju, et al
Programs
OPN-2853
Download PDF
Phase 1b/2a Study of PLX51107, a Small Molecule BET Inhibitor, in Subjects with Advanced Hematological Malignancies and Solid Tumors
AUTHORS
Patnaik, et al
Programs
OPN-2853
Download PDF
Resistance to BET inhibitors involves the Wnt/β-catenin Pathway in Uveal Melanoma
AUTHORS
Ambrosini, et al
Programs
OPN-51107
Download PDF
Response and Resistance to Bromodomain Inhibition in Acute Myeloid Leukemia
AUTHORS
Huang, et al
Programs
OPN-51107
Download PDF